FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA

Their core work

FIBICO is the biomedical research foundation linked to the IMIBIC research institute in Córdoba, Spain. They focus on clinical and translational biomedicine — particularly personalised medicine, infectious disease research, and antimicrobial resistance. Their work spans from training the next generation of biomedical researchers (through fellowship programmes) to contributing clinical data and expertise in large European disease networks. They serve as a bridge between hospital-based clinical practice in southern Spain and EU-wide research consortia.

What they specialise in

How they've shifted over time

FIBICO's early H2020 involvement (2015–2016) was scattered — a digital health procurement project (SAEPP) and a paediatric liver cancer network (ChiLTERN), suggesting they were exploring EU funding opportunities broadly. From 2019 onward, their profile sharpened dramatically around infectious diseases, antimicrobial resistance, and precision medicine, with three projects in these areas plus their own coordinated fellowship programme. The shift from general participation to focused AMR and personalised medicine work signals a maturing research strategy aligned with major European health priorities.

FIBICO is consolidating around antimicrobial resistance and clinical infectious disease research, making them a relevant partner for future AMR-focused consortia, particularly those needing clinical sites in southern Europe.

How they like to work

FIBICO predominantly joins large consortia as a third party (4 of 6 projects), which means they typically contribute specific clinical data, patient cohorts, or expertise without bearing major administrative burden. They coordinated one project (P2Med), their fellowship programme, showing they can lead when the scope is close to their core mission. With 152 unique partners across 22 countries, they are well-connected through the large health consortia they participate in, though these connections are likely inherited from the consortia rather than self-built.

Through participation in large health consortia, FIBICO has touched 152 partners across 22 countries — a broad but largely indirect European network. Their real collaborative depth likely centres on the Spanish biomedical research ecosystem and the specific clinical networks they contribute to.

What sets them apart

FIBICO offers something specific: a clinical biomedical research site in Andalusia with growing expertise in antimicrobial resistance and precision medicine. For consortium builders, they fill the "southern European clinical partner" slot — providing access to patient populations, clinical data, and hospital-embedded research capacity in a region with high AMR prevalence. Their MSCA-COFUND coordination also shows they can manage EU grants, not just contribute to them.

Highlights from their portfolio

• P2Med
  Their only coordinated project (EUR 662K MSCA-COFUND), a fellowship programme for personalised medicine — signals their core institutional mission.
• REVERSE
  Directly addresses AMR prevention in high-prevalence settings, highly relevant given growing European policy focus on antimicrobial resistance.
• 3TR
  A major multi-country project investigating why patients don't respond to treatments in autoimmune diseases — uses advanced single-cell and integrative genomics approaches.